Pharmacology of the short QT syndrome N588K‐hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs
暂无分享,去创建一个
J. Hancox | H. Witchel | H J Witchel | M J McPate | R. S. Duncan | M. McPate | J. Hancox | R S Duncan | J C Hancox | H. Witchel | M. McPate | M. Mcpate
[1] J. Hancox,et al. A method for making rapid changes of superfusate whilst maintaining temperature at 37 degrees C. , 1996, Pflugers Archiv : European journal of physiology.
[2] J. Hancox,et al. A method for making rapid changes of superfusate whilst maintaining temperature at 37°C , 1996, Pflügers Archiv.
[3] Hui-zhen Wang,et al. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels. , 2004, Acta pharmacologica Sinica.
[4] M. Sanguinetti,et al. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Hancox,et al. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline , 1999, British journal of pharmacology.
[6] J. Hancox,et al. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine , 2002, British journal of pharmacology.
[7] H. Witchel,et al. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. , 2001, Biochemical and biophysical research communications.
[8] Martin Borggrefe,et al. Congenital Short QT Syndrome and Implantable Cardioverter Defibrillator Treatment: , 2003, Journal of cardiovascular electrophysiology.
[9] C. January,et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.
[10] Gary Yellen,et al. The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.
[11] Gail A. Robertson,et al. LQT2 : amplitude reduction and loss of selectivity in the tail that wags the HERG channel. , 2000, Circulation research.
[12] H. Duff,et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.
[13] J A Peters,et al. Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.
[14] Ramon Brugada,et al. Short QT Syndrome and Atrial Fibrillation Caused by Mutation in KCNH2 , 2005, Journal of cardiovascular electrophysiology.
[15] J. Hancox,et al. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin , 2007, Biochemical pharmacology.
[16] M. Sanguinetti,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Balser,et al. Probing the Interaction Between Inactivation Gating and d-Sotalol Block of HERG , 2000, Circulation research.
[18] J. Brugada,et al. Idiopathic Short QT Interval:A New Clinical Syndrome? , 2001, Cardiology.
[19] Martin Borggrefe,et al. In vivo Effects of Mutant HERG K+ Channel Inhibition by Disopyramide in Patients with a Short QT‐1 Syndrome: A Pilot Study , 2007, Journal of cardiovascular electrophysiology.
[20] G. Robertson,et al. Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E‐4031 from HERG to M‐eag channels , 1998, The Journal of physiology.
[21] J. Hancox,et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.
[22] C. January,et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.
[23] Michel Haissaguerre,et al. Short QT syndrome: pharmacological treatment. , 2004, Journal of the American College of Cardiology.
[24] Jules C Hancox,et al. The Low-Potency, Voltage-Dependent HERG Blocker Propafenone—Molecular Determinants and Drug Trapping , 2004, Molecular Pharmacology.
[25] Modulation of I Kr inactivation by mutation N 588 K in KCNH 2 : A link to arrhythmogenesis in short QT syndrome , 2005 .
[26] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[27] M. Sanguinetti,et al. A mutation in the pore region of HERG K+ channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation , 1998, The Journal of physiology.
[28] Frank Sachse,et al. De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. , 2005, Cardiovascular research.
[29] Jonathan M. Cordeiro,et al. Modulation of IKr inactivation by mutation N588K in KCNH2: A link to arrhythmogenesis in short QT syndrome , 2005 .
[30] S. Priori,et al. A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene , 2005, Circulation research.
[31] A. Brown,et al. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels. , 2001, Molecular pharmacology.
[32] Jules C Hancox,et al. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. , 2006, Journal of molecular and cellular cardiology.
[33] I. Gussak,et al. Short QT Syndrome , 2005, Annals of Noninvasive Electrocardiology.
[34] R. Brugada,et al. Further Insights into the Effect of Quinidine in Short QT Syndrome Caused by a Mutation in HERG , 2005, Journal of cardiovascular electrophysiology.
[35] Jules C Hancox,et al. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. , 2004, Biochemical and biophysical research communications.
[36] A. V. van Ginneken,et al. Mutation in the KCNQ1 Gene Leading to the Short QT-Interval Syndrome , 2004, Circulation.
[37] J. Hancox,et al. Inhibition of L‐type calcium current by propafenone in single myocytes isolated from the rabbit atrioventricular node , 1997, British journal of pharmacology.
[38] Wei Zhou,et al. Short QT syndrome: a case report and review of literature. , 2006, Resuscitation.
[39] J. Brugada,et al. Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.
[40] Martin Borggrefe,et al. Short QT Syndrome: A Familial Cause of Sudden Death , 2003, Circulation.
[41] Jules C. Hancox,et al. The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: Mechanism of gain-in-function determined at 37 °C , 2005 .
[42] A. Brown,et al. Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.
[43] J C Hancox,et al. Alteration of HERG current profile during the cardiac ventricular action potential, following a pore mutation. , 1998, Biochemical and biophysical research communications.
[44] J. Tamargo,et al. Effects of propafenone on calcium current in guinea‐pig ventricular myocytes , 1993, British journal of pharmacology.
[45] J. Brugada,et al. ECG phenomenon of idiopathic and paradoxical short QT intervals. , 2002, Cardiac electrophysiology review.
[46] Harry J Witchel,et al. The hERG potassium channel as a therapeutic target , 2007, Expert opinion on therapeutic targets.